Related Experiment Videos
Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?
K P Morris1, S Watson, M M Reid
1Department of Paediatric Nephrology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Insights
Children undergoing erythropoietin (EPO) therapy need iron monitoring. Low serum ferritin (≤60 µg/L) predicts iron deficiency, impacting hemoglobin response. Early iron supplementation is crucial for effective EPO treatment in pediatric patients.
Area of Science:
- Pediatric Hematology
- Clinical Nutrition
- Pharmacology
Background:
- Recombinant human erythropoietin (EPO) therapy efficacy is significantly limited by iron deficiency.
- Identifying and monitoring children at risk for iron deficiency during EPO treatment is critical for optimal outcomes.
Purpose of the Study:
- To determine the best methods for identifying and monitoring iron deficiency in children receiving EPO therapy.
- To assess the relationship between iron status parameters and EPO treatment response.
Main Methods:
- Serial measurement of iron status parameters in nine children before and during a 24-week EPO therapy period.
- Evaluation of serum ferritin, hemoglobin, and red cell indices (MCV, hypochromia, microcytosis) as predictors of iron deficiency.
- Assessment of iron treatment efficacy on hemoglobin and iron status.
Main Results:
- Serum ferritin ≤60 µg/L at baseline was the best predictor of developing iron deficiency during EPO therapy.
- Five of nine children developed iron deficiency, evidenced by poor hemoglobin response and microcytosis/hypochromia.
- A falling mean red cell volume (MCV) correlated with a poor EPO response. Iron supplementation improved hemoglobin and iron status, though MCV remained low.
Conclusions:
- Children with serum ferritin ≤60 µg/L or a falling MCV during EPO treatment should receive high-dose oral iron supplementation.
- Proactive iron management is essential for maximizing the therapeutic benefits of EPO in pediatric populations.
- Increased red cell volume distribution width after iron therapy may indicate a positive response to iron supplementation.
Abstract:
Iron deficiency severely limits the efficacy of recombinant human erythropoietin (EPO). In order to determine how best to identify and monitor children at risk of developing iron deficiency, we serially measured several parameters of iron status in nine children before and during a 24-week period of EPO therapy. Serum ferritin was the best predictor of development of iron deficiency, five of the nine children developed iron deficiency, characterised by a poor haemoglobin response or evidence of microcytosis and hypochromia; all had a serum ferritin of 60 micrograms/l or less at the start of EPO. Haemoglobin response was also related to change in mean red cell volume (MCV); a falling MCV, irrespective of absolute value, accompanying a poor response to EPO. Iron treatment in five children resulted in significant improvements in haemoglobin and iron status parameters. Although MCV remained low, there was a marked increase in red cell volume distribution width after iron, which may be of value in monitoring the response to iron therapy. We suggest that children with a serum ferritin of 60 micrograms/l or less and those who develop a falling MCV during EPO treatment should receive high-dose oral iron supplementation before and during treatment with EPO.